Free Trial

AbbVie (ABBV) Stock Price, News & Analysis

$166.51
-0.74 (-0.44%)
(As of 07/8/2024 ET)
Today's Range
$165.62
$167.72
50-Day Range
$154.86
$172.75
52-Week Range
$132.70
$182.89
Volume
3.50 million shs
Average Volume
5.64 million shs
Market Capitalization
$294.03 billion
P/E Ratio
49.41
Dividend Yield
3.72%
Price Target
$181.07

AbbVie MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
8.7% Upside
$181.07 Price Target
Short Interest
Healthy
0.87% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.34
Upright™ Environmental Score
News Sentiment
0.57mentions of AbbVie in the last 14 days
Based on 37 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
12.98%
From $10.71 to $12.10 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.85 out of 5 stars

Medical Sector

36th out of 876 stocks

Pharmaceutical Preparations Industry

10th out of 416 stocks

ABBV stock logo

About AbbVie Stock (NYSE:ABBV)

AbbVie Inc. is a US-based biopharma company with global operations. The company originated as the bio-pharma segment of Abbott Laboratories and was spun off in late 2012. The company officially IPOd on January 2, 2013; contrary to criticisms, the move was solely to protect the parent company from expiring patents. Post-spin, AbbVie emerged as a research-based biopharma that has more than doubled in size. AbbVie, like its parent Abbot Laboratories, is a well-established dividend growth stock.

Over the years, AbbView Inc. has made numerous acquisitions. Among the more notable are ImmuVen, Pharamcyclics and Allergan plc. Allergan plc was an Ireland-based pharmaceutical company focused on health-oriented aesthetic products and is the owner of Botox. Botox accounts for the bulk of the company’s Aesthetics portfolio revenue and about 4% of the net as of 2022. The total revenue in 2021 was $56.20 billion with a 31% operating margin.

Today, AbbVie operates as a diversified multi-national pharmaceutical company with a patient-centric approach to research. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community.

The company’s original winner, Humira, is still the number one revenue source but the portfolio has been greatly expanded. Other profitable therapies include but are not limited to SKYRIZI for psoriasis, RINVOQ for rheumatoid arthritis and IMBRUVICA and VENCLEXTA for chronic leukemia conditions.

The company is focused on research and has a number of collaborations and partnerships to that end. Among the many avenues of research and innovation are the advancement of precision medicine or pMedicine. PMeds are designed not only to target the specific causes of diseases, often at the genetic level, but the patients that are most likely to benefit from them. Assuming there are 2 highly effective drugs for 1 disease, PMedicine seeks to identify which patients respond better to each.

As of 2022, AbbVie employed more than 50,000 people globally with 21,000 in STEM-related positions. To date, the company had invested more than $50 billion into research through more than 250 partnerships. Partnerships are with universities, medical facilities, research organizations and other pharmaceutical companies. The company’s operations span 20 countries, treating more than 60 million people and 40 conditions annually.

AbbVie has 5 focus areas for its research and products. These are Immunology, Oncology, Neurology, Virology and Eye Care. The company has a robust pipeline of new products that are in some stage of clinical trials. In most cases, trials are underway for multiple indications, including some therapies that have already been approved for 1 or more conditions.

AbbVie is a leader in ESG and sustainability. The company is a member of the Fortune 100 and one of the Fortune 100’s “Best Companies To Work For”. It is a Top 50 Company regarding diversification and a member of the Dow Jones Sustainability World Index and the S&P ESG Index. Among its many positions is sustainable operations so it can deliver life-changing therapies to those who need them most.

ABBV Stock Price History

ABBV Stock News Headlines

Financial markets news icon
MarketBeat Week in Review – 7/1 - 7/5 (ABBV)
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season
Pharmacist, scientist developing new medicines, medicaments, pharmacy, chemistry
AbbVie Stock: A Perfect Dip for Investors to Buy
In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & Johnson NYSE: JNJ, which is down 0.68%, and Pfizer Inc. NYSE: PFE, which is down 1.38%.
Bitcoin’s Biggest Year Yet
2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my newest video.
Pharmacist, scientist developing new medicines, medicaments, pharmacy, chemistry
AbbVie Stock: A Perfect Dip for Investors to Buy
ABBV stock is down over 3% to start the second half of the year; the stock may be overvalued in the short term but still offers value for long-term investors
AbbVie Stock: A Perfect Dip for Investors to Buy
In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & Johnson NYSE: JNJ, which is down 0.68%, and Pfizer Inc. NYSE: PFE, which is down 1.38%.
AbbVie (NYSE:ABBV) Stock Price Up 0.1%
AbbVie (NYSE:ABBV) Issues Q2 2024 Earnings Guidance
Bitcoin’s Biggest Year Yet
2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my newest video.
AbbVie (NYSE:ABBV) Updates FY 2024 Earnings Guidance
AbbVie (NYSE:ABBV) Stock Price Down 1.3%
AbbVie (NYSE:ABBV) Stock Price Down 1.7%
AbbVie Inc. (NYSE:ABBV) Sees Large Drop in Short Interest
AbbVie (NYSE:ABBV) Shares Down 0.1%
See More Headlines
Receive ABBV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AbbVie and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 5/15 Dividend
4/12/2024
Last Earnings
5/03/2024
Dividend Payable
5/15/2024
Today
7/09/2024
Ex-Dividend for 8/15 Dividend
7/15/2024
Next Earnings (Confirmed)
7/25/2024
Dividend Payable
8/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
CUSIP
00287Y10
Employees
50,000
Year Founded
2013

Price Target and Rating

Average Stock Price Target
$181.07
High Stock Price Target
$200.00
Low Stock Price Target
$150.00
Potential Upside/Downside
+8.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
14 Analysts

Profitability

Net Income
$4.86 billion
Pretax Margin
13.84%

Debt

Sales & Book Value

Annual Sales
$54.40 billion
Cash Flow
$15.74 per share
Book Value
$5.78 per share

Miscellaneous

Outstanding Shares
1,765,868,000
Free Float
1,761,453,000
Market Cap
$294.03 billion
Optionable
Optionable
Beta
0.64

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Should I Buy AbbVie Stock? ABBV Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in AbbVie:

  • AbbVie Inc. has a strong portfolio of pharmaceutical products, including Humira and Skyrizi, which have shown positive results in treating various diseases.
  • Recent developments in AbbVie's pipeline show promising potential for future growth and expansion in the pharmaceutical industry.
  • AbbVie's stock price has been relatively stable and has shown consistent growth over the past year, making it an attractive investment option.

Cons

Investors should be bearish about investing in AbbVie for these reasons:

  • There may be potential risks associated with AbbVie's heavy reliance on a few key pharmaceutical products, such as Humira, which could impact the company's revenue if faced with competition or patent expirations.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these AbbVie pros and cons to contact@marketbeat.com.

ABBV Stock Analysis - Frequently Asked Questions

How have ABBV shares performed this year?

AbbVie's stock was trading at $154.97 at the start of the year. Since then, ABBV stock has increased by 7.4% and is now trading at $166.51.
View the best growth stocks for 2024 here
.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) announced its earnings results on Friday, May, 3rd. The company reported $2.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.26 by $0.05. The company's quarterly revenue was up .7% on a year-over-year basis.
Read the conference call transcript
.

What is Richard A. Gonzalez's approval rating as AbbVie's CEO?

580 employees have rated AbbVie Chief Executive Officer Richard A. Gonzalez on Glassdoor.com. Richard A. Gonzalez has an approval rating of 88% among the company's employees.

Does AbbVie have any subsidiaries?

AbbVie subsidiaries include Mavupharma, Allergan, Stem CentRx, Pharmacyclics Inc, ImmuVen, AbbVie AB, AbbVie AG, and others.

Who are AbbVie's major shareholders?

Top institutional investors of AbbVie include DNB Asset Management AS (0.03%), Massmutual Trust Co. FSB ADV (0.01%), Woodstock Corp (0.01%) and Neville Rodie & Shaw Inc. (0.01%). Insiders that own company stock include Richard A Gonzalez, Azita Saleki-Gerhardt, Michael Severino, Robert A Michael, Jeffrey Ryan Stewart, Nicholas Donoghoe, Roxanne S Austin, Carrie C Strom, Elaine K Sorg, Scott T Reents, Henry O Gosebruch, Timothy J Richmond, Perry C Siatis, Kevin K Buckbee, Laura J Schumacher and Brian L Durkin.
View institutional ownership trends
.

How do I buy shares of AbbVie?

Shares of ABBV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of AbbVie own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), AT&T (T) and Bristol-Myers Squibb (BMY).

This page (NYSE:ABBV) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners